Internal Medicine, Rheumatology · Nashville, TN
NPI
1417903378
Since 2006
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
2001 Charlotte Ave, Suite #102
Nashville, TN, 37203
Phone (615) 321-3277
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.0M
192,713 services
Medicare patients, 2024
421
Average age 70
Drug cost, 2024
$4.3M
5,918 prescriptions
Company payments, 2025
$2,323
From 17 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Robert P Lagrone was code J0717 (injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)), 104,316 times for 35 patients. In total Robert P Lagrone billed 192,713 services in 36 codes, and Medicare paid $2.0M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2010-04-20.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 104,316 | 35 | $3.60 | $375K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 24,450 | 53 | $24.79 | $606K |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 10,750 | 11 | $9.15 | $98K |
| J0490 Injection, belimumab, 10 mg | Office | 7,182 | 11 | $41.32 | $297K |
| J7050 Infusion, normal saline solution, 250 cc | Office | 635 | 90 | $0.52 | $329 |
| 96413 Chemotherapy Administration | Office | 628 | 90 | $90.14 | $57K |
| 96401 Chemotherapy Administration | Office | 579 | 48 | $50.66 | $29K |
| 99214 Office E&M - Established | Office | 566 | 334 | $84.02 | $48K |
| 99213 Office E&M - Established | Office | 371 | 176 | $56.87 | $21K |
| 96415 Chemotherapy Administration | Office | 360 | 53 | $19.31 | $6,953 |
| 76881 Ultrasound - Nonspecific | Office | 247 | 121 | $34.65 | $8,559 |
| 99212 Office E&M - Established | Office | 71 | 19 | $39.59 | $2,811 |
| 99204 Office E&M - New | Office | 59 | 59 | $99.53 | $5,872 |
| 76882 Ultrasound - Nonspecific | Office | 51 | 26 | $46.25 | $2,359 |
| 99205 Office E&M - New | Office | 17 | 17 | $140.39 | $2,387 |
By year: 2022 $2.4M for 199,127 services; 2023 $2.2M for 206,222 services; 2024 $2.0M for 192,713 services.
Medicare prescription drug claims, 2024
In 2024, the drug Robert P Lagrone prescribed most often to Medicare patients was Prednisone, with 944 prescriptions and refills. In total Robert P Lagrone wrote 5,918 Medicare prescriptions that cost $4.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Prednisone Generic | 944 | 1,813 | 402 | $11K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 543 | 543 | 69 | $16K |
| Methotrexate Methotrexate Sodium | 406 | 744 | 148 | $14K |
| Duloxetine Hcl Generic | 383 | 779 | 106 | $8,139 |
| Tizanidine Hcl Generic | 286 | 527 | 110 | $3,866 |
| Tramadol Hcl Generic | 261 | 263 | 57 | $3,030 |
| Gabapentin Generic | 253 | 300 | 54 | $3,272 |
| Trazodone Hcl Generic | 250 | 450 | 76 | $3,730 |
| Hydroxychloroquine Sulfate Generic | 248 | 549 | 86 | $12K |
| Leflunomide Generic | 147 | 339 | 59 | $12K |
| Enbrel Sureclick Etanercept | 105 | 110 | 18 | $823K |
| Pregabalin Generic | 89 | 145 | 23 | $1,524 |
| Rinvoq Upadacitinib | 83 | 87 | 14 | $565K |
| Meloxicam Generic | 80 | 152 | 29 | $320 |
| Cyclobenzaprine Hcl Generic | 80 | 152 | 26 | $781 |
Brand drugs: - claims; generic drugs: 5,342 claims; opioid claims: 870.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Robert P Lagrone $2,323 ($2,323 in general payments such as food, travel and fees) from 17 companies. The largest payer was Abbvie Inc. with $399.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.